GlaxoSmithKline’s Nucala (mepolizumab) last month became the first and only biologic treatment approved in the US for Hypereosinophilic Syndrome (HES).
A few months into the pandemic, the world is now moving beyond managing the crisis, with more focus on addressing the collateral damages and shaping the future.
Parents’ willingness to vaccinate children has been boosted by the COVID-19 pandemic, but safety fears mean few are willing to take their child to a medical centre to receive jabs, accordin